SCIREQ is preparing for the upcoming Experimental Biology Meeting that will take place in Orlando from April 6-9, 2019. At this meeting we launch our latest development: the vivoFlow – WBP (Whole Body Plethysmograph Chamber). The vivoFlow is fully compatible with our current system and has several design features which both improve data quality and usability.
The advantages of the vivoFlow – WBP
Collect Data Sooner with reduced acclimation time:
The amber tinted whole body plethysmograph chamber reduces acclimation time and variability between baseline values. Mice do not typically see amber wavelengths, the tinting allows them to quickly adjust to the chamber and settle into a quiet breathing pattern. Learn more about all new features here
Improved Data Reproducibility:
Patented concentric pneumotachograph for industry leading noise cancellation.
Removable bucket chamber and removable hinged lid allows fast cleaning, easy placement and removal of subjects.
Fully Integrated System:
Separate module encloses sensitive components preventing risk of damage while allowing easy removal of the subject chamber for cleaning.
Plethysmography is a versatile tool for assessing ventilatory parameters in pre-clinical studies, common applications include: asthma, control or breathing, gas challenges, just to name a few.
A focus during this year’s EB Meeting will be on opioid-induced respiratory depression. Central nervous system respiratory depression is a well-known side-effect of the opioid drug family and respiratory depression is the primary cause of fatal opioid overdose. Opioid research studies are needed to gain a better understanding of the pathways involved in opioid-induced respiratory depression and tolerance.
vivoFlow – WBP permits a continuous and non-invasive approach to assess changes in conscious respiratory behaviour which result from drug administration. It is the ideal approach to monitor the real-time effects on ventilatory behaviour of fentanyl, oxycodone, morphine and many others.
A recent example is that of Hill et al., where they examined both the signalling profile of the novel µ-opioid receptor ligand PZM21, and its capacity to induce respiratory depression. Respiratory rate and tidal volume were assessed using whole body plethysmograph chamber, comparing saline control and morphine-treated subjects to those administered PZM21. The authors’ present evidence for a dose-dependent decrease in respiratory rate, without tidal volume effects, in a similar fashion to that observed for morphine.
The benefits of this approach are:
- Easy-to-use, no surgery required
- Tracks conscious subjects’ ability to respond to real-time changes
- Swivel/tether system for measurement of physiological parameters (EEG). drug infusion or blood sampling
- Integrates easily with gas challenges, through use of automated mass flow controllers
- Measures respiratory rate (RR), estimated tidal volume (VT), minute ventilation (MV), flow rates
There is a lot to discuss at the conference! Please reserve some time in your schedule to visit our booth 914. We will gladly present the vivoFlow and answer any questions you might have.
Experimental Biology 2019, Orlando – Florida
Exhibit Dates / Hours:
April 7-9, 2019: 9am – 4pm
We are looking forward to seeing you in Orlando!
Your SCIREQ Team
About SCIREQ & emka
Our dedicated team of engineers and scientists develop sophisticated scientific tools that yield reproducible data of unsurpassed accuracy and detail. SCIREQ is involved at both the inhalation exposure model generation and assessing pulmonary, cardio and neuro function in the resultant model and is best known for its flexiVent,– the gold standard for in vivo lung function measurements.